ArticleFoods (Basel, Switzerland)2026
Separation, Purification, Structural Characterization and Hypoglycemic Effect Study of Homogeneous
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extraction, Purification, Structural Characterization, and In Vitro Simulated Digestion of Polysaccharides fromFoods (Basel, Switzerland) · 2026Article
- A Water-Soluble Polysaccharide fromFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectives
methodsMFP-III, representing the final gel-filtration homogeneous fraction, was purified using defined procedures: DEAE-52 cellulose chromatography followed by Sephadex G-100 gel filtration. Purity and homogeneity were validated by high-performance liquid chromatography (HPLC). Structural characteristics were analyzed via HPLC, GC-MS, FTIR, and NMR spectroscopy. Meanwhile, hypoglycemic activity of MFP-III was evaluated.
resultsMFP-III (94.2 ± 2.6%) has a molecular weight of approximately 6.83 kDa, primarily composed of rhamnose, arabinose, galactose, glucose, mannose, and galacturonic acid. Its backbone structure is presumed to be →2,4)-α-L-Rhap-(1 → 4)-α-D-GalpA-(1→, with branching units potentially attached to O-4. MFP-III demonstrated significant inhibitory activity against α-glucosidase (IC
conclusionsThe findings provide preliminary insights into the hypoglycemic structure-activity relationship of MFP-III, providing data support for the development of blood glucose-lowering natural inhibitors, and offering a theoretical foundation for advancing the application of polysaccharides from other sources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.